Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12942535 | 0.84 | SLC7A5 (0.39) | SLC7A5CYP3A4HSD17B10SLC1A3PKM | |
| SCHEMBL13284685 | 0.79 | ALDH1A1 (0.38) | SLC7A5CYP3A4CYP1A2CYP2C9HIF1A | |
| Histidine SCHEMBL3498728 | 0.74 | CYP3A4 (0.97) | SLC7A5CYP3A4CYP1A2NFKB1THPO | |
| Hydrochloric Acid SCHEMBL25254223 | 0.72 | SLC22A6 (0.39) | KDM4EALDH1A1LMNAMAPTPMP22 | |
| Histidine SCHEMBL388560 | 0.71 | CYP3A4 (1.00) | SLC7A5CYP3A4CYP1A2NFKB1THPO | |
| Histidine SCHEMBL30852263 | 0.71 | CYP3A4 (1.00) | SLC7A5CYP3A4CYP1A2NFKB1THPO | |
| SCHEMBL5320498 | 0.71 | SLC7A5 (0.51) | SLC7A5CYP3A4HSD17B10PKMALPI | |
| Histidine SCHEMBL19974306 | 0.71 | CYP3A4 (1.00) | SLC7A5CYP3A4CYP1A2NFKB1THPO | |
| D-Histidine SCHEMBL288043 | 0.71 | CYP3A4 (1.00) | SLC7A5CYP3A4CYP1A2NFKB1THPO | |
| Histidine SCHEMBL137600 | 0.71 | CYP3A4 (1.00) | SLC7A5CYP3A4CYP1A2NFKB1THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2210882-A1 | Synthesis of new protected azahistidine, their processes and their use in synthesises | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081882-A2 | SYNTHESIS OF NEW PROTECTED AZAHISTIDINES, THEIR PROCESSES AND THEIR USE IN SYNTHESISES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2010-07-22 | — | — | WO | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | SLC7A5 50/4885CYP3A4 2439/4885HSD17B10 3760/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | SLC7A5 39/4885CYP3A4 2540/4885HSD17B10 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.